CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

dapagliflozin/metformin hydrochloride

Last Updated: December 1, 2015
Result type: Reports
Project Number: SR0468-000
Product Line: Reimbursement Review

Generic Name: dapagliflozin/metformin hydrochloride

Brand Name: XigDuo

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: Diabetes Mellitus, Type 2

Indications: Diabetes Mellitus, Type 2

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 20, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions